Post-Marketing Surveillance of Perjeta in Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 18 Jun 2019 Planned End Date changed from 28 May 2019 to 28 May 2021.
- 18 Jun 2019 Planned primary completion date changed from 28 May 2019 to 28 May 2021.
- 02 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.